NovoCure (NVCR) Operating Margin Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -343.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -178.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 487.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -283.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2,016.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 1,505.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -184.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -3,846.00 |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 1,058.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,058.00 |
| Dec 31, 2025 | 1,030.00 |
| Sep 30, 2025 | -276.00 |
| Jun 30, 2025 | -989.00 |
| Mar 31, 2025 | -2,384.00 |
| Dec 31, 2024 | -2,169.00 |
| Sep 30, 2024 | -1,429.00 |
| Jun 30, 2024 | -1,313.00 |
| Mar 31, 2024 | -2,991.00 |
| Dec 31, 2023 | -4,706.00 |
| Sep 30, 2023 | -5,707.00 |
| Jun 30, 2023 | -5,546.00 |
| Mar 31, 2023 | -4,599.00 |
| Dec 31, 2022 | -3,362.00 |
| Sep 30, 2022 | -2,297.00 |
| Jun 30, 2022 | -1,638.00 |
| Mar 31, 2022 | 776.00 |
| Dec 31, 2021 | -513.00 |
| Sep 30, 2021 | 170.00 |
| Jun 30, 2021 | 231.00 |
| Mar 31, 2021 | 2,426.00 |
| Dec 31, 2020 | 1,680.00 |
| Sep 30, 2020 | 2,314.00 |
| Jun 30, 2020 | 4,622.00 |
| Mar 31, 2020 | 3,502.00 |
| Dec 31, 2019 | 5,927.00 |
| Sep 30, 2019 | 13,460.00 |
| Jun 30, 2019 | 20,919.00 |
| Mar 31, 2019 | 23,633.00 |
| Dec 31, 2018 | 23,473.00 |
| Sep 30, 2018 | 26,262.00 |
| Jun 30, 2018 | 40,429.00 |
| Mar 31, 2018 | 39,707.00 |
| Dec 31, 2017 | 59,694.00 |
| Sep 30, 2017 | 39,754.00 |